All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/adv melanoma (mML), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 066, 2015 0.42 [0.25; 0.72]
CheckMate 066 DUPLICATE, 2015 0.36 [0.24; 0.55]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.65 [0.53; 0.80]
CheckMate 238, 2017 0.87 [0.66; 1.14]
IMspire-150 (BRAF mutant), 2020 0.85 [0.65; 1.12]
IMspire-170, 2020 1.06 [0.69; 1.62]
KEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96]
KEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
KEYNOTE-022, 2019 0.76 [0.41; 1.40]
0.70 [0.61 ; 0.80 ] CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 12 57% 5,914 low low deaths (OS) (extension)detailed results CheckMate 066, 2015 0.46 [0.36; 0.59]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.83 [0.67; 1.03]
KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.65 [0.54 ; 0.78 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 69% 2,791 low not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
KEYNOTE 054 (all population), 2018 0.53 [0.37; 0.76]
0.64 [0.47 ; 0.87 ] CheckMate 238, 2017, KEYNOTE 054 (all population), 2018 2 48% 1,754 low not evaluable PFS (extension)detailed results CheckMate 066, 2015 0.42 [0.33; 0.53]
CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.79 [0.65; 0.97]
KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.58 [0.48 ; 0.70 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 77% 2,791 low not evaluable progression or deaths (PFS)detailed results CheckMate 066, 2015 0.43 [0.34; 0.55]
CheckMate 066 DUPLICATE, 2015 0.43 [0.34; 0.55]
CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.74 [0.60; 0.92]
IMspire-150 (BRAF mutant), 2020 0.78 [0.63; 0.97]
IMspire-170, 2020 1.15 [0.88; 1.50]
KEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64]
KEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
KEYNOTE-022, 2019 0.66 [0.40; 1.08]
0.61 [0.52 ; 0.72 ] CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 11 79% 5,008 low low RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
KEYNOTE 054 (all population), 2018 0.56 [0.47; 0.67]
KEYNOTE 054 (PDL1>1%), 2018 0.57 [0.43; 0.75]
0.62 [0.52 ; 0.73 ] CheckMate 238, 2017, KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 3 46% 2,778 low not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
IMMUNED (N vs P ; all population), 2020 0.56 [0.33; 0.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.40 [0.20; 0.79]
KEYNOTE 054 (all population), 2018 0.57 [0.43; 0.75]
KEYNOTE 054 (PDL1>1%), 2018 0.54 [0.42; 0.69]
0.58 [0.50 ; 0.66 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 5 0% 3,004 low not evaluable DCRdetailed results IMspire-170, 2020 0.91 [0.63; 1.32]
0.91 [0.63 ; 1.32 ] IMspire-170, 2020 1 0% 446 NA not evaluable DMFSdetailed results KEYNOTE 054 (all population), 2018 0.60 [0.49; 0.73]
KEYNOTE 054 (PDL1>1%), 2018 0.60 [0.49; 0.73]
0.60 [0.52 ; 0.69 ] KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 2 0% 1,872 low not evaluable DORdetailed results KEYNOTE-022, 2019 0.41 [0.20; 0.83]
0.41 [0.20 ; 0.83 ] KEYNOTE-022, 2019 1 0% 81 NA not evaluable DOR (extension)detailed results CheckMate 066, 2015 3.45 [1.46; 8.18]
3.45 [1.46 ; 8.18 ] CheckMate 066, 2015 1 0% 120 NA not evaluable objective responses (ORR)detailed results CheckMate 066, 2015 4.06 [2.52; 6.54]
CheckMate 066 DUPLICATE, 2015 4.06 [2.52; 6.54]
CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.76 [1.28; 2.41]
IMspire-150 (BRAF mutant), 2020 1.19 [0.83; 1.71]
IMspire-170, 2020 0.77 [0.50; 1.17]
KEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80]
KEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
KEYNOTE-022, 2019 0.68 [0.32; 1.47]
2.58 [1.68 ; 3.97 ] CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 11 89% 5,008 low low objective responses (ORR) (extension)detailed results CheckMate 066, 2015 4.50 [2.79; 7.25]
CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.96 [4.16; 8.54]
4.57 [3.31 ; 6.32 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 50% 1,679 low not evaluable AE (any grade)detailed results CheckMate 066, 2015 0.78 [0.34; 1.76]
CheckMate 238, 2017 0.49 [0.20; 1.23]
IMspire-170, 2020 14.27 [3.34; 61.03]
KEYNOTE 054 (all population), 2018 1.51 [0.96; 2.38]
KEYNOTE-022, 2019 2.03 [0.18; 23.06]
1.49 [0.61 ; 3.64 ] CheckMate 066, 2015, CheckMate 238, 2017, IMspire-170, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-022, 2019 5 76% 2,883 low not evaluable AE (grade 3-4)detailed results CheckMate 066, 2015 0.84 [0.56; 1.25]
CheckMate 238, 2017 0.28 [0.21; 0.37]
IMspire-170, 2020 4.03 [2.70; 6.00]
KEYNOTE 054 (all population), 2018 2.03 [1.52; 2.73]
KEYNOTE-022, 2019 2.44 [1.17; 5.12]
1.34 [0.47 ; 3.82 ] CheckMate 066, 2015, CheckMate 238, 2017, IMspire-170, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-022, 2019 5 97% 2,883 low not evaluable AE leading to death (grade 5)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 1.23 [0.42; 3.56]
IMspire-170, 2020 1.39 [0.43; 4.44]
KEYNOTE-022, 2019 4.10 [0.18; 92.93]
1.34 [0.65 ; 2.76 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-022, 2019 6 0% 1,695 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 066, 2015 0.55 [0.28; 1.10]
CheckMate 238, 2017 0.15 [0.10; 0.21]
IMMUNED (N vs P ; all population), 2020 3.57 [0.71; 18.07]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.33 [4.34; 29.62]
IMspire-150 (BRAF mutant), 2020 0.78 [0.47; 1.29]
KEYNOTE-022, 2019 2.58 [1.16; 5.75]
1.28 [0.36 ; 4.56 ] CheckMate 066, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-022, 2019 6 95% 2,164 low serious AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 066, 2015 0.61 [0.29; 1.28]
CheckMate 238, 2017 0.11 [0.07; 0.18]
IMMUNED (N vs P ; all population), 2020 4.90 [0.55; 43.46]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.38 [3.94; 32.84]
1.26 [0.15 ; 10.80 ] CheckMate 066, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 4 96% 1,534 low not evaluable SAE (any grade)detailed results CheckMate 066, 2015 0.73 [0.49; 1.10]
IMMUNED (N vs P ; all population), 2020 1.27 [0.56; 2.87]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.69 [1.68; 8.08]
1.45 [0.55 ; 3.84 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 3 85% 628 low not evaluable SAE (grade 3-4)detailed results CheckMate 066, 2015 0.74 [0.47; 1.17]
IMMUNED (N vs P ; all population), 2020 2.51 [0.94; 6.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.48 [1.58; 7.66]
1.77 [0.60 ; 5.28 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 3 85% 629 low not evaluable STRAE (any grade)detailed results CheckMate 066, 2015 1.06 [0.54; 2.07]
IMMUNED (N vs P ; all population), 2020 6.13 [1.29; 29.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.69 [2.43; 13.31]
IMspire-150 (BRAF mutant), 2020 1.24 [0.85; 1.81]
KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
1.36 [0.75 ; 2.47 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 82% 2,206 low not evaluable STRAE (grade 3-4)detailed results CheckMate 066, 2015 0.99 [0.44; 2.27]
IMMUNED (N vs P ; all population), 2020 19.34 [1.09; 342.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.68 [1.93; 11.38]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
2.45 [0.78 ; 7.74 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 55% 1,696 low not evaluable TRAE (any grade)detailed results CheckMate 066, 2015 0.93 [0.60; 1.46]
CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.58 [1.88; 6.81]
CheckMate 238, 2017 0.25 [0.15; 0.43]
IMMUNED (N vs P ; all population), 2020 4.29 [1.74; 10.57]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.07 [1.04; 24.68]
IMspire-150 (BRAF mutant), 2020 0.82 [0.11; 5.85]
KEYNOTE 054 (all population), 2018 1.79 [1.36; 2.37]
KEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26]
KEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
KEYNOTE-022, 2019 1.36 [0.29; 6.34]
1.21 [0.81 ; 1.80 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 13 85% 6,192 low low TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.62 [0.35; 1.08]
CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.82 [3.41; 6.80]
CheckMate 238, 2017 0.20 [0.14; 0.27]
IMMUNED (N vs P ; all population), 2020 5.85 [1.58; 21.65]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.66 [2.91; 15.27]
IMspire-150 (BRAF mutant), 2020 1.41 [0.93; 2.12]
KEYNOTE 054 (all population), 2018 4.93 [2.87; 8.48]
KEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91]
KEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
KEYNOTE-022, 2019 3.60 [1.67; 7.74]
1.32 [0.70 ; 2.51 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 13 96% 6,192 low low TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
KEYNOTE-022, 2019 2.02 [0.07; 61.28]
1.09 [0.37 ; 3.25 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 11 0% 5,269 low low TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.85 [3.25; 7.24]
CheckMate 238, 2017 0.12 [0.08; 0.17]
IMMUNED (N vs P ; all population), 2020 7.29 [0.86; 61.51]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.33 [4.34; 29.62]
KEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87]
KEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
KEYNOTE-022, 2019 2.67 [1.18; 6.03]
1.50 [0.57 ; 3.95 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 10 96% 4,258 low low TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.10 [3.17; 8.19]
CheckMate 238, 2017 0.09 [0.05; 0.15]
IMMUNED (N vs P ; all population), 2020 9.90 [0.53; 186.01]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.38 [3.94; 32.84]
KEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76]
KEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.60 [0.40 ; 6.41 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 95% 4,139 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 238, 2017 0.50 [0.02; 14.96]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.77 [0.21 ; 2.78 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 3,851 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
1.45 [0.11 ; 19.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.45 [0.57 ; 3.70 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018 6 0% 3,384 low not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.22 ; 4.21 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 2,395 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
KEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88]
KEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81]
KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.39 [0.12 ; 1.24 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 8% 2,395 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.01 [0.18; 22.24]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.25 [0.01; 5.62]
IMspire-150 (BRAF mutant), 2020 1.44 [0.48; 4.34]
KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.30 [0.64 ; 2.62 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 0% 6,072 low low Asthenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.50 [0.02; 14.88]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 238, 2017 0.25 [0.03; 2.24]
IMspire-150 (BRAF mutant), 2020 2.47 [0.45; 13.60]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.73 [0.32 ; 1.67 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 0% 4,843 low not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
3.02 [0.28 ; 33.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.72 [0.06 ; 9.49 ] IMMUNED (N vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020 2 0% 618 low not evaluable Chills TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.73 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,285 moderate not evaluable Chorioretinopathy TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.61 [0.02 ; 18.27 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 9.36 [2.80; 31.26]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.40 [0.31; 130.93]
KEYNOTE 054 (all population), 2018 10.04 [1.28; 78.73]
KEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13]
KEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
1.09 [0.30 ; 3.99 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 82% 4,245 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.16 ; 5.50 ] CheckMate 066, 2015, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 0% 2,177 moderate not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.25 [0.01; 5.54]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.97 [0.25 ; 3.82 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 2,946 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 8.09 [0.43; 153.69]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 0.30 [0.01; 6.77]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.05 [0.33 ; 3.30 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 0% 4,156 low low Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
KEYNOTE 054 (all population), 2018 9.95 [0.54; 182.62]
KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
2.27 [0.52 ; 9.86 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-006 (3 week), 2015 5 0% 2,667 low serious Diarrhoea TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.18; 22.23]
CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.45 [1.60; 7.41]
CheckMate 238, 2017 0.15 [0.07; 0.34]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.06; 16.70]
IMspire-150 (BRAF mutant), 2020 0.53 [0.16; 1.76]
KEYNOTE 054 (all population), 2018 1.32 [0.29; 5.92]
KEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81]
KEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
0.76 [0.35 ; 1.62 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 69% 6,072 low low Dizziness TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.96 [0.06 ; 15.59 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.23 [0.37 ; 4.12 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 0% 4,156 low critical Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.96 [0.06 ; 15.59 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.96 [0.06 ; 15.59 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.42 [0.43 ; 4.65 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,546 low not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.50 [0.62; 48.70]
KEYNOTE 054 (all population), 2018 18.05 [1.04; 312.27]
6.23 [1.33 ; 29.21 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018 3 0% 1,229 low not evaluable Erythema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 7.41 [0.37; 148.78]
7.41 [0.37 ; 148.78 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
1.45 [0.11 ; 19.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.25 [0.01; 5.51]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.48 [1.26; 15.87]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 3.70 [0.38; 35.82]
KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10]
KEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11]
KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.76 [0.37 ; 1.58 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 11 35% 5,061 low low Gastritis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
2.32 [0.20 ; 26.84 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 9.36 [1.13; 77.61]
KEYNOTE 054 (all population), 2018 5.01 [1.09; 22.98]
1.57 [0.10 ; 24.07 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018 4 91% 2,134 low not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
2.32 [0.20 ; 26.84 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 238, 2017 0.14 [0.02; 1.15]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.60 [0.19 ; 1.92 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 3,851 low serious Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.15 [0.55; 186.51]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.31 [0.64; 17.15]
KEYNOTE 054 (all population), 2018 6.99 [0.86; 56.99]
KEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
3.83 [1.67 ; 8.76 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 0% 4,245 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 7.53 [1.60; 35.49]
1.42 [0.07 ; 29.90 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 3 91% 1,123 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 238, 2017 2.01 [0.07; 59.97]
1.49 [0.11 ; 19.39 ] CheckMate 066, 2015, CheckMate 238, 2017 2 0% 1,316 low not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.96 [0.06 ; 15.59 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.05 [0.30; 121.25]
CheckMate 238, 2017 1.00 [0.06; 16.07]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.40 [0.31; 130.93]
IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.67 [0.63 ; 4.40 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 0% 6,072 low low Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.06 [0.59; 43.61]
CheckMate 238, 2017 0.18 [0.04; 0.81]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.67 [0.27 ; 1.64 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 17% 5,150 low low Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.97 [0.33 ; 2.85 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 11 0% 5,561 low low Increase AST TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.06; 16.02]
CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.68 [1.96; 22.80]
CheckMate 238, 2017 0.10 [0.02; 0.44]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.01 [0.75; 12.00]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
1.14 [0.33 ; 3.90 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 69% 3,851 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.18; 22.23]
CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.29 [2.52; 21.10]
CheckMate 238, 2017 0.18 [0.07; 0.48]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.47 [1.46; 20.45]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
1.32 [0.37 ; 4.69 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 79% 3,851 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.60 [1.37; 4.95]
IMMUNED (N vs P ; all population), 2020 0.91 [0.17; 4.70]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.01 [0.75; 12.00]
IMspire-150 (BRAF mutant), 2020 0.99 [0.64; 1.52]
1.47 [0.89 ; 2.43 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020 5 48% 1,979 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.97 [0.10 ; 9.43 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 3 0% 629 low not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.12 [0.01; 2.33]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17]
KEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17]
0.16 [0.04 ; 0.65 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 5 0% 1,328 low serious Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 238, 2017 0.05 [0.00; 0.95]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMspire-150 (BRAF mutant), 2020 1.36 [0.78; 2.37]
KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.34 [0.84 ; 2.14 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 11 0% 5,061 low low Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.06; 16.70]
1.29 [0.15 ; 11.24 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.16 [0.01; 3.31]
0.96 [0.03 ; 31.61 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 63% 218 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
KEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50]
KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.18 [0.45 ; 3.05 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 0% 4,156 low critical Myocarditis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.16 ; 5.51 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 0% 2,296 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 14.30 [0.81; 253.04]
CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 0.17 [0.02; 1.40]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.56 [0.23 ; 1.37 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 0% 6,072 low low Nephritis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 3.96 [0.18; 87.96]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.03 [0.15 ; 6.90 ] KEYNOTE 054 (all population), 2018, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 2,078 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.04; 5.68]
1.07 [0.16 ; 7.27 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.05 [0.00; 0.92]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39]
KEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.20 [0.06 ; 0.72 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 2,395 moderate serious Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.96 [0.06 ; 15.59 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 0.99 [0.06; 15.81]
KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
1.12 [0.24 ; 5.34 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 5 0% 1,928 low not evaluable Pancytopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.16 [0.01; 3.29]
0.16 [0.01 ; 3.29 ] CheckMate 066, 2015 1 0% 411 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.75 [0.18 ; 3.09 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 2,395 moderate serious Peripheral neuropathy TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
KEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29]
KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32]
0.51 [0.10 ; 2.70 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 4 0% 917 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84]
1.22 [0.02 ; 61.84 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
KEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
2.07 [0.79 ; 5.39 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 0% 4,756 low low Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.96 [0.13 ; 6.82 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 2,317 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.10 [0.73; 50.95]
CheckMate 238, 2017 0.10 [0.01; 1.82]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.31 [0.52 ; 3.29 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 0% 6,072 low low Pyrexia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.50 [0.02; 14.88]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
IMspire-150 (BRAF mutant), 2020 1.22 [0.24; 6.13]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.09 [0.41 ; 2.86 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 0% 4,362 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.30 [1.31; 80.93]
CheckMate 238, 2017 0.35 [0.13; 0.98]
IMspire-150 (BRAF mutant), 2020 0.98 [0.53; 1.81]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.86 [0.44 ; 1.66 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 18% 5,854 low low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
0.98 [0.15 ; 6.59 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018 4 22% 2,134 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.97 [0.10 ; 9.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018 3 0% 1,229 low not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
5.95 [0.30 ; 119.02 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.17 [0.32; 31.48]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
0.85 [0.14 ; 5.17 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE 054 (all population), 2018 4 59% 2,134 low not evaluable Stomatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
0.96 [0.06 ; 15.59 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 218 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.05 [0.00; 0.82]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
0.23 [0.06 ; 0.85 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 5 0% 1,328 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 13:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
